364TiPAnti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. (23rd October 2018) - Decker, T; Denkert, C; Lübbe, K; Müller, V; Mundhenke, C; Furlanetto, J; Schmidt, M; Thill, M; Tierbach, V; Seither, F; Loibl, S